Peptide-Major Histocompatibility Complexes presenting MAGE-A4, NY-ESO-1, and PRAME on HLA (pMHC (MAGE-A4/NY-ESO-1/PRAME))

These complexes consist of specific peptide fragments derived from the cancer-testis antigens (CTAs) MAGE-A4, NY-ESO-1, and PRAME, presented on Human Leukocyte Antigen (HLA) molecules, most commonly the HLA-A*02:01 allele. Under normal physiological conditions, these intracellular proteins are restricted to immune-privileged germ cells in the testes but are frequently overexpressed in various solid tumors, providing a highly specific window for therapeutic intervention (PubMed: 31515458). Because these antigens are processed intracellularly and presented as peptides on the cell surface via MHC Class I, they allow the immune system to target oncogenic proteins that are otherwise inaccessible to traditional antibody-based therapies (Nature Reviews Cancer, 2021). Therapeutic strategies targeting these pMHC complexes primarily involve T-cell receptor (TCR) engineered T-cell therapies and TCR-bispecific engagers. For instance, Afamitresgene autoleucel targets MAGE-A4 and has received FDA approval for synovial sarcoma, while candidates like IMA203 target PRAME in advanced solid tumors (FDA.gov, 2024; Immatics, 2023). These therapies rely on the high affinity and specificity of the engineered TCR to recognize the peptide-HLA complex, triggering a potent cytotoxic response against the tumor cell. Monitoring HLA status and antigen expression levels is critical for patient selection and predicting treatment efficacy.

Other names

Cancer-testis antigen peptide-MHC complexesMAGE-A4/NY-ESO-1/PRAME HLA-A*02 complexesTumor-specific HLA-presented peptidesMHC-presented Cancer-Testis Antigens

Targeting of these complexes is achieved through engineered T-cell receptors (TCRs) or TCR-based bispecific molecules that specifically bind the peptide-HLA complex on the tumor cell surface, leading to T-cell mediated cytotoxicity and cytokine release.